Aastrom Reports Data and Safety Monitoring Board Recommendation to Continue ixCELL-DCM Clinical Trial
09 avr. 2014 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Announces Appointments of Dr. Ross Tubo as Chief Scientific Officer and Dr. David Recker as Chief Medical Officer
01 avr. 2014 08h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 1, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at the 2014 Regen Med Investor Day
19 mars 2014 09h02 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 19, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Fourth-Quarter and Year-End 2013 Financial Results
13 mars 2014 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 13, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Host Fourth Quarter 2013 Investor Call on March 13, 2014
06 mars 2014 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 6, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Enters Into $15 Million Equity Commitment With Lincoln Park Capital
27 janv. 2014 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
19 déc. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Regains Compliance With NASDAQ Equity Standard Listing Requirement
15 nov. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 15, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results
12 nov. 2013 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at the 2013 Therapeutic Area Partnerships Conference
12 nov. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...